Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Mahadevia
Parthiv J
PJ
Malinoski
Frank J
FJ
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D001249:Asthma / Q000191:economics / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006801:Humans; D007223:Infant; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000191:economics / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab